Saturday 17 October 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024. In the quarter to June 2026, revenue grew 45.4%, EPS grew 100.0%, free cash flow grew 8.47% and total debt rose 5.20%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
30.56
1.20
−3.78%
Follow CAI
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 |
P/S ratio |
5.56 | 0.00 | 0.00 |
Altman Z-Score |
3.55 | — | — |
Altman Z″-Score (non-manufacturers) |
(0.93) | (28.44) | — |
P/FCF ratio |
67.44 | 0.00 | 0.00 |
Beneish M-Score |
(2.71) | — | — |
P/Operating CF |
100.74 | (31.83) | (31.83) |
P/B ratio |
7.81 | 0.00 | 0.00 |
Price to Tangible BV |
8.09 | 0.00 | 0.00 |
EV/Sales |
5.04 | 0.00 | 0.00 |
EV/EBITDA |
50.81 | 0.00 | 0.00 |
EV/Operating CF |
49.19 | (4.73) | (4.73) |
EV/FCF |
61.14 | (4.55) | (4.55) |
Quick Ratio |
7.17 | 0.94 | — |
Current Ratio |
7.85 | 1.30 | — |
Net Debt/EBITDA |
(5.23) | (1.55) | 0.00 |
Debt/Assets |
33.67% | 110.41% | 0.00% |
Debt/Equity |
0.66 | (0.15) | 0.00 |
Asset Turnover |
1.11 | 2.40 | 0.00 |
Operating CF/Net income |
(0.15) | 0.65 | 0.60 |
Capex/Depreciation |
(0.46) | (0.15) | (0.41) |
Interest Coverage |
0.79 | (5.14) | (10.11) |
| 55.99% | 0.00% | 0.00% | |
| (73.22%) | (220.09%) | 0.00% | |
ROIC |
18.05% | 0.00% | 0.00% |
Return on Tangible Assets |
(57.61%) | (320.22%) | 0.00% |
Average Days of Receivables |
50.41 | 78.13 | 0.00 |
Research and Development Expense of Revenue |
12.51% | 27.63% | 38.18% |
Selling, General and Administrative Expense of Revenue |
48.33% | 78.10% | 95.38% |
Intangible Assets out of Total Assets |
0.02 | 0.06 | 0.00 |
Share Based Compensation of Revenue |
8.62% | 4.52% | 4.98% |
Graham Net Nets |
0.10 | (2.63) | (2.63) |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(38.81%) | (54.72%) | (54.72%) |
Free Cash Flow Yield |
1.48% | (28.84%) | (28.84%) |
Revenue per Share |
4.86 | 11.61 | 8.76 |
Operating CF per Share |
0.50 | (6.91) | (7.90) |
Capex per Share |
(0.10) | (0.24) | (0.64) |
Free Cash Flow per Share |
0.40 | (7.15) | (8.54) |
Cash per Share |
4.79 | 1.91 | 0.00 |
Shareholders Equity per Share |
3.45 | (70.40) | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
3.45 | (70.40) | 0.00 |
Free Cash Flow |
66.90 | (253.64) | (298.42) |
Working Capital |
870.66 | 50.31 | — |
Capital Expenditures |
(16.26) | (8.44) | (22.32) |
Net Current Asset Value |
449.44 | (2,626.84) | 0.00 |
EV/EBIT |
90.66 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.02 | 0.07 |
Price to Operating Income |
100.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.56 | 0.83 | 0.00 |
Cash ROIC |
3.81% | 12.36% | 0.00% |
Accounts Receivable Turnover |
8.10 | 0.00 | 0.00 |
Accounts Payable Turnover |
8.15 | 0.00 | 0.00 |
Inventory Turnover |
5.29 | 0.00 | 0.00 |
Average Days of Payables |
52.44 | 43.45 | 0.00 |
Days of Inventory on Hand |
85.11 | 61.86 | 0.00 |
Average Receivables |
100.19 | — | — |
Average Payables |
33.50 | — | — |
Average Inventory |
51.60 | — | — |
Average Assets |
734.70 | 171.87 | — |
Average Common Equity |
(960.77) | — | — |
Columns are period end dates